Integrase  ||| S:0 E:10 ||| JJ
inhibitors ||| S:10 E:20 ||| NN
:  ||| S:20 E:22 ||| :
why  ||| S:22 E:26 ||| WRB
do  ||| S:26 E:29 ||| VBP
we  ||| S:29 E:32 ||| PRP
need  ||| S:32 E:37 ||| VBP
a  ||| S:37 E:39 ||| DT
new  ||| S:39 E:43 ||| JJ
drug  ||| S:43 E:48 ||| NN
class  ||| S:48 E:54 ||| NN
for  ||| S:54 E:58 ||| IN
HIV  ||| S:58 E:62 ||| NNP
therapy ||| S:62 E:69 ||| NN
?  ||| S:69 E:71 ||| .
The  ||| S:71 E:75 ||| DT
introduction  ||| S:75 E:88 ||| NN
of  ||| S:88 E:91 ||| IN
integrase  ||| S:91 E:101 ||| JJ
inhibitors  ||| S:101 E:112 ||| NN
as  ||| S:112 E:115 ||| IN
a  ||| S:115 E:117 ||| DT
new  ||| S:117 E:121 ||| JJ
drug  ||| S:121 E:126 ||| NN
class  ||| S:126 E:132 ||| NN
for  ||| S:132 E:136 ||| IN
treatment  ||| S:136 E:146 ||| NN
of  ||| S:146 E:149 ||| IN
HIV  ||| S:149 E:153 ||| NNP
have  ||| S:153 E:158 ||| VBP
added  ||| S:158 E:164 ||| VBN
a  ||| S:164 E:166 ||| DT
very  ||| S:166 E:171 ||| RB
potent  ||| S:171 E:178 ||| JJ
and  ||| S:178 E:182 ||| CC
extremely  ||| S:182 E:192 ||| RB
well  ||| S:192 E:197 ||| RB
tolerated  ||| S:197 E:207 ||| JJ
new  ||| S:207 E:211 ||| JJ
treatment  ||| S:211 E:221 ||| NN
option  ||| S:221 E:228 ||| NN
to  ||| S:228 E:231 ||| TO
the  ||| S:231 E:235 ||| DT
HIV-armentarium ||| S:235 E:250 ||| JJ
.  ||| S:250 E:252 ||| .
Particularly  ||| S:252 E:265 ||| RB
in  ||| S:265 E:268 ||| IN
patients  ||| S:268 E:277 ||| NNS
with  ||| S:277 E:282 ||| IN
previously  ||| S:282 E:293 ||| RB
developed  ||| S:293 E:303 ||| VBN
drug  ||| S:303 E:308 ||| NN
resistance ||| S:308 E:318 ||| NN
,  ||| S:318 E:320 ||| ,
the  ||| S:320 E:324 ||| DT
availability  ||| S:324 E:337 ||| NN
of  ||| S:337 E:340 ||| IN
new  ||| S:340 E:344 ||| JJ
active  ||| S:344 E:351 ||| JJ
drugs  ||| S:351 E:357 ||| NNS
offers  ||| S:357 E:364 ||| VBZ
great  ||| S:364 E:370 ||| JJ
hope ||| S:370 E:374 ||| NN
.  ||| S:374 E:376 ||| .
Moreover ||| S:376 E:384 ||| RB
,  ||| S:384 E:386 ||| ,
the  ||| S:386 E:390 ||| DT
in  ||| S:390 E:393 ||| IN
general  ||| S:393 E:401 ||| JJ
excellent  ||| S:401 E:411 ||| JJ
safety  ||| S:411 E:418 ||| NN
profile  ||| S:418 E:426 ||| NN
offers  ||| S:426 E:433 ||| VBZ
numerous  ||| S:433 E:442 ||| JJ
opportunities  ||| S:442 E:456 ||| NNS
for  ||| S:456 E:460 ||| IN
all  ||| S:460 E:464 ||| DT
lines  ||| S:464 E:470 ||| NNS
of  ||| S:470 E:473 ||| IN
therapy  ||| S:473 E:481 ||| NN
and  ||| S:481 E:485 ||| CC
special  ||| S:485 E:493 ||| JJ
patient  ||| S:493 E:501 ||| NN
populations ||| S:501 E:512 ||| NNS
.  ||| S:512 E:514 ||| .
Clearly  ||| S:514 E:522 ||| RB
more  ||| S:522 E:527 ||| JJR
data  ||| S:527 E:532 ||| NNS
is  ||| S:532 E:535 ||| VBZ
needed  ||| S:535 E:542 ||| VBN
to  ||| S:542 E:545 ||| TO
further  ||| S:545 E:553 ||| RB
explore  ||| S:553 E:561 ||| VB
and  ||| S:561 E:565 ||| CC
define  ||| S:565 E:572 ||| VB
the  ||| S:572 E:576 ||| DT
future  ||| S:576 E:583 ||| JJ
role  ||| S:583 E:588 ||| NN
of  ||| S:588 E:591 ||| IN
integrase  ||| S:591 E:601 ||| JJ
inhibitors  ||| S:601 E:612 ||| NN
in  ||| S:612 E:615 ||| IN
HIV-care ||| S:615 E:623 ||| JJ
.  ||| S:623 E:625 ||| .
